

Does depression and anxiety increase subclinical atherosclerosis more in dyslipidemic women than men?

Lale Tokgozoglu and Ugur Canpolat

European Journal of Preventive
Cardiology
0(00) 1–3
© The European Society of
Cardiology 2019
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/2047487319883722
journals.sagepub.com/home/cpr



Atherosclerotic cardiovascular disease (ASCVD) is a risk factor-driven immuno-inflammatory condition. In addition to causal risk factors such as apo-B-containing lipoproteins, hypertension and smoking, psychosocial factors including depression and anxiety are considered to be risk modifiers and may play a role in the initiation, progression and complications of ASCVD. The presence of more than one risk factor has been shown to increase the risk of developing ASCVD exponentially.^{1–7} Psychosocial stress may increase cardiovascular risk by causing low adherence to medications, life-style modification and cardiac rehabilitation. Furthermore, chronic stress may lead to maladaptive immune, endocrine and metabolic responses as well as hypothalamic–pituitary–adrenal axis dysfunction, sympathetic hyperactivity, endothelial dysfunction, pro-inflammatory and pro-thrombotic states.² The INTERHEART study was one of the largest studies to show that self-reported psychosocial factors are associated with the risk of the first myocardial infarction independent of socioeconomic status and smoking. In the INTERHEART study, the population attributable risk was 40% in women and 25% in men.⁸

In the current issue of the journal, Ellins et al.⁹ report an association of depression and anxiety and dyslipidemia with subclinical atherosclerosis represented by carotid intima media thickness (cIMT) using cross-sectional phase 7 data of the Whitehall II Study ($n = 3934$, 71.7% men). Depression and anxiety was pre-defined by the general health questionnaire score and Center for Epidemiologic Studies Depression (CES-D) scale, or a previous diagnosis of depression, or using anti-depressant/anxiolytic medication. Depression and anxiety was present in 37% of the study population (33% in men vs. 47% in women). Study results suggested that women with both depression and anxiety and dyslipidemia had a greater cIMT after adjusting for confounding factors. However, there was no association between depression and anxiety and cIMT in men with and without dyslipidemia.

Despite a strong cause–effect relation of major cardiovascular risk factors including dyslipidemia with

subclinical atherosclerosis,^{1,10} conflicting data was found about the impact of psychological abnormalities including depression and anxiety on subclinical atherosclerosis.^{11–13} In the Three-City Study, Prugger et al.¹⁴ showed that subclinical atherosclerosis using cIMT was longitudinally associated with the progression of depressive symptoms (CES-D score) at 10-year follow-up both in elderly women and men. In contrast, in the Baltimore Longitudinal Study of Aging, there was no association between depressive symptoms (CES-D score) and cIMT among healthy community-dwelling volunteers.¹³ cIMT has been used in several studies, especially in younger populations as a surrogate marker for subclinical atherosclerosis.¹² However, recent studies have shown that two-dimensional and preferably three-dimensional carotid ultrasound for plaque detection and calcium scoring are better predictors of cardiovascular risk.¹⁵

The current study suggests that women with both depression and anxiety and dyslipidemia are potentially at the greatest risk of cardiovascular disease (CVD). The results of the current study should be interpreted carefully with regard to the association of depression and anxiety and dyslipidemia with subclinical atherosclerosis (cIMT) because of the very small magnitude of the associations assessed by Cohen's D values. In addition, the use of anti-depressants (2.5% in men vs. 4.4% in women, $P = 0.001$) and lipid-lowering therapy (12% in men vs. 9.1% in women, $P = 0.01$) rates were significantly different between genders which might have had an impact on study outcomes. The overall difference in cIMT was lost when the depression and anxiety group was categorised into depression only versus anxiety

Department of Cardiology, Hacettepe University Faculty of Medicine, Turkey

Corresponding author:

Lale Tokgozoglu, Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Email: laletok@gmail.com

only versus depression and anxiety after adjusting for confounding factors.

The question raised by this study is whether dyslipidemic women with depression and anxiety are more likely to develop subclinical atherosclerosis than dyslipidemic men with depression and anxiety. Stress has been associated with poorer cardiovascular health metrics in both men and women.⁶ The type of stress also makes a difference. Studies have shown that work-related stress increases cardiovascular risk more in men whereas chronic stress may be more strongly associated with CVD risk in women.^{16–18} If women are repeatedly faced with psychosocial risk factors, they may respond with biological reactions that accelerate the atherosclerotic process. It has been suggested that stress-mediated cardiovascular biological reactions lead to atherosclerosis by the way of changes in shear stress and catecholamine release which cause endothelial disruption and facilitate the infiltration of lipids and pro-inflammatory cells into the intima media, leading to the formation of atherosclerotic plaque. Experimental evidence showed that stress-related hyperlipidemia and enhanced oxidative stress have been closely associated with the atherosclerotic process.¹⁹ In the Stockholm Female Coronary Angiography Study,¹⁶ the impact of psychosocial stress on the progression of coronary atherosclerosis using serial quantitative coronary angiography has been investigated. Hyperlipidemia was more prevalent in women patients with moderate or high job stress in the study. During the 3-year follow-up, there was more pronounced coronary atherosclerosis progression in women with baseline psychosocial stress. Furthermore, greater pulse pressure during stress, as well as at rest, was shown to be a marker of compromised compliance in the arterial wall indicative of increased risk in women.²⁰ There are also studies suggesting that the immune response leading to ASCVD in women may differ from men.²¹ However, the lack of association of pro-inflammatory markers (C-reactive protein and/or interleukin 6) with cIMT and lack of prognostic data in this study make it difficult to explain the underlying biological mechanisms relating depression and anxiety with subclinical atherosclerosis in dyslipidemic women.

One important finding of this study is the high rates of depression and anxiety in this population. The diagnostic algorithm used by the authors for defining depression and anxiety was sensitive yielding a high number of persons classified as having depression and anxiety (33 % in men and 47% in women). Comorbid chronic or transient depression and anxiety is prevalent in 20% of patients with CVD.¹⁸ The rates of depression and anxiety in the EUROASPIRE IV survey hospital arm were also very high especially for women.²² There were also temporal changes of depression and anxiety

prevalence and symptoms among each EUROASPIRE survey. This may explain one of the main limitations of the spot assessment of depression and anxiety scale/questionnaires in the current study. Multimorbidity and psychological abnormalities such as depression and anxiety covary in a dose-dependent manner and have a temporally bi-directional relationship.²³ Therefore, it is difficult to differentiate the association between psychological wellbeing and CVD from the cause–effect relationship.

Prospective studies with repeated measures of psychological stress, biomarkers and cardiovascular outcomes are needed to see if depression and anxiety has differential effects in men and women. Meanwhile, it is important to address psychosocial stress as a risk modifier in all our patients and implement stress management strategies. Biological and behavioural abnormalities should be treated together by integrated care in the cardiac rehabilitation setting placing the patient at the centre.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

References

1. Libby P, Buring JE, Badimon L, et al. Atherosclerosis. *Nat Rev Dis Primers* 2019; 5: 56.
2. Lichtman JH, Froelicher ES, Blumenthal JA, et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. *Circulation* 2014; 129: 1350–1369.
3. Tully PJ, Cosh SM and Baumeister H. The anxious heart in whose mind? A systematic review and meta-regression of factors associated with anxiety disorder diagnosis, treatment and morbidity risk in coronary heart disease. *J Psychosom Res* 2014; 77: 439–448.
4. Steptoe A and Kivimaki M. Stress and cardiovascular disease: an update on current knowledge. *Annu Rev Public Health* 2013; 34: 337–354.
5. Gale CR, Batty GD, Osborn DP, et al. Mental disorders across the adult life course and future coronary heart disease: evidence for general susceptibility. *Circulation* 2014; 129: 186–193.
6. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation* 2019; 140: e596–e646.

7. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). *Eur Heart J* 2016; 37: 2315–2381.
8. Rosengren A, Hawken S, Ounpuu S, et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. *Lancet* 2004; 364: 953–962.
9. Ellins EA, Shipley MJ, Rees DA, et al. Associations of depression-anxiety and dyslipidaemia with subclinical carotid arterial disease: findings from the Whitehall II Study. *Eur J Prev Cardiol*. Epub ahead of print 17 September 2019. DOI: 10.1177/2047487319876230.
10. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J*. Epub ahead of print 2019. DOI: 10.1016/j.atherosclerosis.2019.08.014.
11. Ali SS, Khan SA, Khosa F, et al. Noninvasive assessment of subclinical atherosclerosis in persons with symptoms of depression. *Atherosclerosis* 2017; 264: 92–99.
12. Elovainio M, Keltikangas-Jarvinen L, Kivimaki M, et al. Depressive symptoms and carotid artery intima-media thickness in young adults: the Cardiovascular Risk in Young Finns Study. *Psychosom Med* 2005; 67: 561–567.
13. Rice SC, Zonderman AB, Metter EJ, et al. Absence of relation between depressive symptoms and carotid intimal medial thickness in the Baltimore Longitudinal Study of Aging. *Psychosom Med* 2009; 71: 70–76.
14. Prugger C, Godin O, Perier MC, et al. Longitudinal association of carotid plaque presence and intima-media thickness with depressive symptoms in the elderly: the three-city study. *Arterioscler Thromb Vasc Biol* 2015; 35: 1279–1283.
15. Papageorgiou N, Briasoulis A, Androulakis E, et al. Imaging subclinical atherosclerosis: where do we stand? *Curr Cardiol Rev* 2017; 13: 47–55.
16. Wang HX, Leineweber C, Kirkeeide R, et al. Psychosocial stress and atherosclerosis: family and work stress accelerate progression of coronary disease in women. The Stockholm Female Coronary Angiography Study. *J Intern Med* 2007; 261: 245–254.
17. Belkic KL, Landsbergis PA, Schnall PL, et al. Is job strain a major source of cardiovascular disease risk? *Scand J Work Environ Health* 2004; 30: 85–128.
18. Pedersen SS, von Kanel R, Tully PJ, et al. Psychosocial perspectives in cardiovascular disease. *Eur J Prev Cardiol* 2017; 24: 108–115.
19. Devaki M, Nirupama R and Yajurvedi HN. Chronic stress-induced oxidative damage and hyperlipidemia are accompanied by atherosclerotic development in rats. *Stress* 2013; 16: 233–243.
20. Matthews KA, Owens JF, Kuller LH, et al. Stress-induced pulse pressure change predicts women's carotid atherosclerosis. *Stroke* 1998; 29: 1525–1530.
21. Fairweather D. Sex differences in inflammation during atherosclerosis. *Clin Med Insights Cardiol* 2014; 8: 49–59.
22. Pogoseva N, Kotseva K, De Bacquer D, et al. Psychosocial risk factors in relation to other cardiovascular risk factors in coronary heart disease: results from the EUROASPIRE IV survey. A registry from the European Society of Cardiology. *Eur J Prev Cardiol* 2017; 24: 1371–1380.
23. Birk JL, Kronish IM, Moise N, et al. Depression and multimorbidity: considering temporal characteristics of the associations between depression and multiple chronic diseases. *Health Psychol* 2019; 38: 802–811.